Oedema, hypertension and cardiac failure have been reported in association with NSAID treatment. Clinical trial and epidemiological data suggest that use of some NSAIDs, (particularly at high doses and in long term treatment) may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke), (see Precautions). There is insufficient data to exclude such a risk for flurbiprofen 8.75 mg lozenges.
The following list of adverse effects relates to those experienced with flurbiprofen at OTC doses for short term use: (Very common (≥1/10), Common (≥1/100 to <1/10), Uncommon (≥1/1000 to <1/100), Rare (≥1/10000 to <1/1000), Very rare (<1/10000), not known (cannot be estimated from the available data).
Blood and lymphatic system disorders: Not known: anaemia, thrombocytopenia.
Immune system disorders: Rare: anaphylactic reaction.
Psychiatric disorders: Uncommon: insomnia.
Cardiovascular and cerebrovascular disorders: Not known: Oedema, hypertension and cardiac failure.
Nervous system disorders: Common: dizziness, headache, paraesthesia.
Uncommon: somnolence.
Respiratory, thoracic and mediastinal disorders: Common: throat irritation.
Uncommon: exacerbation of asthma and bronchospasm, dyspnoea, wheezing, oropharyngeal blistering, pharyngeal hypoaesthesia.
Gastrointestinal disorders: Common: diarrhoea, mouth ulceration, nausea, oral pain, paraesthesia oral, oropharyngeal pain, oral discomfort (warm or burning feeling or tingling of the mouth).
Uncommon: abdominal distension, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, glossodynia, dysgeusia, oral dysaesthesia, vomiting.
Hepatobiliary disorders: Not known: hepatitis.
Skin and subcutaneous tissue disorders: Uncommon: various skin rashes, pruritus.
Not known: severe forms of skin reaction such as bullous reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis.
General disorders and administration site conditions: Uncommon: pyrexia, pain.
View ADR Reporting Link